Acute passive cigarette smoke exposure and inhaled human insulin (Exubera^®) pharmacokinetics

Authors: Fountaine, Robert; Milton, Ashley; Checchio, Tina; Wei, Greg; Stolar, Marilyn; Teeter, John; Jaeger, Rudolph; Fryburg, David

Source: British Journal of Clinical Pharmacology, Volume 65, Number 6, June 2008 , pp. 864-870(7)

Publisher: Wiley-Blackwell

Buy & download fulltext article:

You have access to the full text article on a website external to ingentaconnect.

Please click here to view this article on Wiley Online Library.

You may be required to register and activate access on Wiley Online Library before you can obtain the full text. If you have any queries please visit Wiley Online Library

Abstract:

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT

• Active cigarette smoking is associated with increased permeability of the pulmonary alveolar epithelium, resulting in faster absorption of inhaled drugs such as Exubera® (EXU). Absorption of EXU is increased approximately twice to four times as much in chronic smokers compared with nonsmokers.

• The rate of clearance of radioaerosols such as technetium-labelled diethylenetriamine penta-acetic acid is decreased in response to passive smoke exposure.

WHAT THIS STUDY ADDS

• Passive smoke exposure causes a decrease in lung permeability, an effect opposite to that of active smoking.

• Acute passive smoke exposure results in a decrease in EXU bioavailability and does not create a risk of hypoglycaemia.

• These results are consistent with previous studies of radioaerosol lung clearance. AIMS

Relative to nonsmokers, the bioavailability of inhaled human insulin (Exubera®; EXU) is markedly increased in chronic smokers. The pharmacokinetics of EXU following passive cigarette smoke exposure is unknown. METHODS

In an open-label, crossover study, healthy nonsmoking volunteers received two treatments in randomized sequence separated by a 2-week wash-out: (i) EXU 3 mg with no passive smoke exposure and (ii) EXU 3 mg after passive smoke exposure (atmospheric nicotine levels 75-125 μg m⁻³) for 2 h. Blood samples were obtained at prespecified times up to 6 h after EXU administration. RESULTS

Twenty-seven subjects completed both study periods. Mean plasma insulin AUC₀₋₃₆₀ decreased by 17% [ratio 83%, 95% confidence interval (CI) 68.8, 99.5] and mean C_max by 29% (ratio 71%, 95% CI 59.8, 83.1) after passive cigarette smoke exposure. The median (range) t_max was 60 min (20-120 min) and 75 min (20-360 min) in the EXU with no exposure and EXU passive exposure groups, respectively. EXU was well tolerated. CONCLUSIONS

Unlike active chronic smoking, acute passive cigarette smoke exposure modestly decreases EXU bioavailability and thus should not increase hypoglycaemia risk. These results are consistent with those from published literature involving technetium-labelled diethylenetriamine penta-acetic acid and suggest that passive cigarette smoke exposure causes an acute decrease in lung permeability vs. active smoking, which causes an increase in permeability.

Keywords: inhaled human insulin; passive smoking; pharmacokinetics

Document Type: Research article

DOI: http://dx.doi.org/10.1111/j.1365-2125.2008.03122.x

Affiliations: 1: Environmental Medicine Incorporated, Westwood, NJ, USA

Publication date: 2008-06-01